Anti-VEGF antibodies

Details Anti-VEGF antibodies Anti-VEGF antibodies

2005-04-26

2005-04-26

Helms, Larry R. (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S320100, C530S387300, C530S388850

Reexamination Certificate

active

06884879

ABSTRACT:
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5580723 (1996-12-01), Wells et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 20020032315 (2002-03-01), Baca et al.
patent: 0 451 216 (1996-01-01), None
patent: 2 188 638 (1987-10-01), None
patent: 2 268 744 (1994-01-01), None
patent: 9109967 (1991-07-01), None
patent: 9222653 (1992-12-01), None
patent: 9404679 (1994-03-01), None
patent: 9410202 (1994-05-01), None
patent: 9630046 (1996-10-01), None
patent: WO 9845331 (1998-10-01), None
patent: WO 9845332 (1998-10-01), None
Yelton et al., J of Immunology 155:1994-2004, 1995.*
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies,”Growth Factors7:53-64 (1992).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo,”Nature362:841-844 (1993).
Alberts et al.,Molecular Biology of the Cell,3rd Ed., Garland Publishing, p. 1154 (1994).
Chothia et al., “Domain Association in Immunoglobulin Molecules The Packing of Variable Domains”J. Mol. Biol.,186:651-663 (1985).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”J. Mol. Biol.,224:487-499 (1992).
Queen et al., “A Humanized Antibody that Binds to the Interleukin 2 Receptor,”PNAS USA,86:10029-10033 (1989).
Kettleborough et al., “Humanization of a Mouse Monoclonal Antibody by the CDR-Grafting: The Importance of Framework Residues on Loop Conformation”Protein Eng.,4(7):773-783 (1991).
Tempest et al., “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in vivo”Biotechnology,9:266-271 (1991).
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving their Ligand-Binding Properties,”Mol. Immunol.,28(4/5):489-198 (1991).
Roguska et al., “Humanization of Murine Monoclonal Antibodies Through Variable Domain Resurfacing”PNAS USA,91:969-973 (1994).
Studnicka et al., “Human-Engineered Monoclonal Antibodies Retain Full Specific Binding Activity by Preserving non-CDR Complementarity-Modulating Residues”Protein Eng.,7:805 (1994).
Allen et al., “Specificity of the T Cell Receptor: Two Different Determinants are Generated by the Same Peptide and the I-akMolecule1,2”J. Immunol.,135:368-373 (1985).
Carter et al., “Humanization of an anti-p185HER2Antibody for Human Cancer Therapy”PNAS USA,89:4285-4289 (1992).
Presta et al., “Humanization of an Antibody Directed Against IgE”,J. Immunol.,151:2623-2632 (1993).
Eigenbrot et al., X-Ray Structure of Fragments from Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VHResidues 59-65″Proteins,18:49-62 (1994).
Shalaby et al., “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene”J. Exp. Med.,175:217-225 (1992).
Kabat et al.,Sequences of Proteins of Immunological Interest,U.S. Dept. Of Health and Human Services, NIH, 5th edition, vol. 1:103-108, 324-331 (1991).
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab”J. Biol. Chem.,271:22611-22618 (1996).
Novotný and Haber, “Structural Invariants of Antigen Binding; Comparison of Immunoglobulin VL-VHand VL-VLDomain Dimers”Proc. Natl. Acad. Sci. USA,82:4592-4596 (1985).
Bending, M.M. “Humanization of Rodent Monoclonal Antibodies,”Methods: A Companion to Methods In Enyzmology8:83-93 (1994).
Baca et al, “Antibody Humanization Using Monovalent Phage Display,”Journal of Biological Chemistry272(16):10678-10684 (1997).
Garrard et al., “Assembly and Enrichment in a Monovalent Phage Display System,”Biotechnology,9:1373-1377 (1991).
Chang et al., “High-level secretion of human growth hormone byEscherichia coli,” Gene, 55:189-196 (1987).
Kunkel et al., “Efficient Site-Directed Mutagenesis Using Uracil-Containing DNA,”Methods Enzymol.,204:125-139 (1991).
Winter et al., “Making Antibodies by Phage Display Technology,”Ann. Rev. Immunol.,12:433-455 (1994).
Vieira et al., “Production of Single-Stranded Plasmid DNA,”Methods Enzymol.,153:3-11 (1987).
Karlsson et al., “Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system,”J. Immun. Methods,145:229-240 (1991).
Cunningham et al., “Production of an atrial natriuretic peptdie variant that is specific for type a receptor”,EMBO J.13(11):2508-2515 (1994).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display,” Biochemistry, 30:10832-10838 (1991).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,” J. Mol. Biol. 226:889-896 (1992).
Folkman et al., “Angiogenesis,”J. Biol. Chem.,267(16):10931-10934 (1992).
Klagsbrun et al., “Regulators of Angiogenesis,”Annu. Rev. Physiol.,53:217-239 (1991).
Garner, A., “Vascular Diseases”,Pathobiology of Ocular Disease. A Dynamic Approach.2nd Ed. (Garner and Klintworth, eds.) Marcel Dekker:New York, pp. 1625-1710 (1994).
Weidner et al., “Tumor Angiongenesis and Metastasis—Correlation in Invasive Breast Carcinoma,”New Engl. J. Med.,324(1):1-8 (1991).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer,”Lancet,340:1120-1124 (1992).
Macchiarini et al., “Relation of neovascularisation to metastasis of non-small-cell lung cancer,”Lancet,340:145-146 (1992).
Good et al., “A tumor suppressor-dependent inhibitor of angiongenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin,”Proc. Natl. Acad. Sci. USA,87:6624-6628 (1990).
Clapp et al., “The 16-Kilodalton N-Terminal Fragment of Human Prolactin is a Potent Inhibitor of Angiogenesis,”Endocrinology,133(3):1292-1299 (1993).
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”Cell,79:315-328 (1994).
O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,”Cell,88:277-285 (1997).
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor,”Endocr. Rev.,18(1):4-25 (1997).
Berkman et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms,”J. Clin. Invest.,91:153-159 (1993).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer,”Human Pathol.,26(1):86-91 (1995).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelila Growth Factor) and its Receptors in Adenocarcinomas of the Gastrointestinal Tract,”Cancer Res.,53:4727-4735 (1993).
Mattern et al., “Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma,”Brit. J. Cancer,73:931-934 (1996).
Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis,”Am. J. Pathol.,146(5):1029-1039 (1995).
Aiello et al., &#

Affiliated with

Also associated with

Rating

Anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3378301